Steroid hormone agonists and antagonists in the treatment of cancer

Cancer Invest. 1992;10(1):27-41. doi: 10.3109/07357909209032786.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Androgen Antagonists / metabolism
  • Androgen Antagonists / pharmacology*
  • Androgens / metabolism
  • Androgens / pharmacology*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism
  • Epidermal Growth Factor / metabolism
  • Estrogen Antagonists / metabolism
  • Estrogen Antagonists / pharmacology*
  • Estrogens / metabolism
  • Estrogens / pharmacology*
  • Female
  • Fibroblast Growth Factor 1 / metabolism
  • Fibroblast Growth Factor 2 / metabolism
  • Flutamide / therapeutic use
  • Humans
  • Insulin-Like Growth Factor I / metabolism
  • Insulin-Like Growth Factor II / metabolism
  • Male
  • Platelet-Derived Growth Factor / metabolism
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / metabolism
  • Receptors, Estrogen / physiology
  • Tamoxifen / therapeutic use
  • Transforming Growth Factor beta / metabolism

Substances

  • Androgen Antagonists
  • Androgens
  • Estrogen Antagonists
  • Estrogens
  • Platelet-Derived Growth Factor
  • Receptors, Estrogen
  • Transforming Growth Factor beta
  • Tamoxifen
  • Fibroblast Growth Factor 2
  • Fibroblast Growth Factor 1
  • Epidermal Growth Factor
  • Insulin-Like Growth Factor I
  • Insulin-Like Growth Factor II
  • Flutamide